About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker HLN · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 2, 2026EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,…
ACETAMINOPHEN; ASPIRIN; CAFFEINE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020802 ↗
Jun 26, 2026CHILDRENS ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020589 ↗
May 1, 2026JUNIOR STRENGTH ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020944 ↗
May 1, 2026CHILDRENS ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020589 ↗
Apr 14, 2026ABREVA
DOCOSANOL
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020941 ↗
Mar 27, 2026ALLI
ORLISTAT
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021887 ↗
Dec 19, 2025CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF
FLUTICASONE PROPIONATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA205434 ↗
Dec 19, 2025FLONASE SENSIMIST ALLERGY RELIEF
FLUTICASONE FUROATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022051 ↗
Sep 15, 2025FLONASE SENSIMIST ALLERGY RELIEF
FLUTICASONE FUROATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022051 ↗
May 5, 2025ADVIL DUAL ACTION WITH ACETAMINOPHEN, ADVIL DUAL ACTION WIT…
ACETAMINOPHEN; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA211733 ↗
Mar 17, 2025NICORETTE, NICORETTE PEPPERMINT, NICORETTE CHERRY PEPPERMINT
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA022360 ↗
Jan 10, 2025CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF
FLUTICASONE PROPIONATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA205434 ↗
Jan 10, 2025FLONASE SENSIMIST ALLERGY RELIEF
FLUTICASONE FUROATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022051 ↗
Jan 8, 2025ADVIL LIQUI-GELS, ADVIL MIGRAINE, ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020402 ↗
Letter or label ↗
Dec 30, 2024ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA018989 ↗
Nov 21, 2024NICORETTE, NICORETTE PEPPERMINT, NICORETTE CHERRY PEPPERMINT
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA022360 ↗
Oct 24, 2024CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF
FLUTICASONE PROPIONATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA205434 ↗
Letter or label ↗
Oct 24, 2024FLONASE SENSIMIST ALLERGY RELIEF
FLUTICASONE FUROATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022051 ↗
Letter or label ↗
Sep 9, 2024ADVIL PM
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA021393 ↗
Sep 6, 2024NICORETTE
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021330 ↗
Aug 7, 2024VOLTAREN ARTHRITIS PAIN
DICLOFENAC SODIUM
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022122 ↗
Apr 30, 2024NICORETTE, NICORETTE PEPPERMINT, NICORETTE CHERRY PEPPERMINT
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022360 ↗
Jan 3, 2024NICORETTE 4MG FRUIT CHILL GUM, LIL DRUG STORE, NICORETTE OR…
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020066 ↗
Jan 3, 2024NICORETTE ORIGINAL, NICORETTE MINT, NICORETTE CINNAMON SURG…
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA018612 ↗
Nov 29, 2023VOLTAREN ARTHRITIS PAIN
DICLOFENAC SODIUM
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022122 ↗
Nov 15, 2023CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF
FLUTICASONE PROPIONATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA205434 ↗
Nov 15, 2023FLONASE SENSIMIST ALLERGY RELIEF
FLUTICASONE FUROATE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022051 ↗
Letter or label ↗
May 15, 2023EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,…
ACETAMINOPHEN; ASPIRIN; CAFFEINE
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA020802 ↗
Apr 17, 2023EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,…
ACETAMINOPHEN; ASPIRIN; CAFFEINE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020802 ↗
Feb 23, 2023ADVIL LIQUI-GELS, ADVIL MIGRAINE, ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020402 ↗
Feb 21, 2023VOLTAREN ARTHRITIS PAIN
DICLOFENAC SODIUM
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022122 ↗
Feb 21, 2023ADVIL PM- DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLET, COA…
DIPHENHYDRAMINE CITRATE; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021394 ↗
Nov 23, 2022VOLTAREN ARTHRITIS PAIN
DICLOFENAC SODIUM
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA022122 ↗
Sep 20, 2022CHILDRENS ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA020589 ↗
Feb 8, 2022ADVIL, ADVIL MENSTRUAL PAIN
IBUPROFEN SODIUM
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA201803 ↗
Jan 25, 2022ADVIL DUAL ACTION WITH ACETAMINOPHEN, ADVIL DUAL ACTION WIT…
ACETAMINOPHEN; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA211733 ↗
Jan 25, 2022ADVIL LIQUI-GELS, ADVIL MIGRAINE, ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020402 ↗
Letter or label ↗
Jan 11, 2022ADVIL PM
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021393 ↗
Jan 10, 2022ADVIL DUAL ACTION WITH ACETAMINOPHEN, ADVIL DUAL ACTION WIT…
ACETAMINOPHEN; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA211733 ↗
Jan 10, 2022ADVIL PM- DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLET, COA…
DIPHENHYDRAMINE CITRATE; IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021394 ↗
Dec 14, 2021ADVIL
IBUPROFEN
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA018989 ↗
Letter or label ↗
Dec 7, 2021EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,…
ACETAMINOPHEN; ASPIRIN; CAFFEINE
HLN
Haleon US Holdings
New drug (NDA), supplement
Manufacturing (CMC)
NDA020802 ↗
Nov 23, 2021ADVIL ALLERGY AND CONGESTION RELIEF, ADVIL MULTI-SYMPTOM CO…
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHL…
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022113 ↗
Nov 23, 2021ADVIL ALLERGY SINUS
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROC…
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021441 ↗
Nov 19, 2021ADVIL SINUS CONGESTION AND PAIN
IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022565 ↗
Nov 19, 2021ADVIL COLD AND SINUS
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021374 ↗
Nov 19, 2021ADVIL COLD AND SINUS
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA019771 ↗
Nov 9, 2021NICORETTE
NICOTINE POLACRILEX
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA021330 ↗
Nov 3, 2021VOLTAREN ARTHRITIS PAIN
DICLOFENAC SODIUM
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA022122 ↗
Nov 3, 2021EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,…
ACETAMINOPHEN; ASPIRIN; CAFFEINE
HLN
Haleon US Holdings
New drug (NDA), supplement
Labeling
NDA020802 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:18 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates